The earnings call highlighted significant revenue growth and successful product launches, underpinned by strategic investments and advancements in the pipeline. However, challenges such as pricing pressures, a decline in Trulicity revenue, and supply constraints in certain regions tempered the overall positive outlook.

Company Guidance

During the Eli Lilly Q4 2024 earnings call, the company provided guidance for 2025, outlining expectations for continued growth. For 2025, they anticipate revenue between $58 billion and $61 billion, representing approximately 32% growth compared to 2024. Key growth drivers include U.S. incretin class expansion, with expectations for Mounjaro international revenue to become more significant in the latter half of 2025. They forecast a decline in Trulicity volume due to shifts toward newer incretins. Additionally, oncology, neuroscience, and immunology are projected to contribute to revenue growth, with a focus on new product launches like Ebglyss, Jaypirca, Omvoh, and Kisunla. The company expects a net price decline in the mid- to high-single digits, impacted by U.S. Part D changes and foreign exchange headwinds. The estimated effective tax rate is around 16%, with projected non-GAAP EPS between $22.50 and $24.00. Gross margin as a percentage of revenue is expected to improve, reflecting operational leverage and product mix optimization.

Record-Breaking Revenue Growth

Full year revenue grew 32% compared to 2023, exceeding guidance by $4 billion. Revenue grew 45% in the most recent quarter.

Strong Product Launches and Pipeline Advances

Successful launches of Mounjaro and Zepbound, both contributing significantly to revenue. Positive Phase III results for imlunestrant, insulin efsitora alfa, and several tirzepatide trials.

Expansion and Innovation Initiatives

Acquisitions and collaborations with Morphic Therapeutics and OpenAI. Investments in manufacturing facilities totaling over $23 billion since 2020.

New Product Approvals

Regulatory approvals for Kisunla, Ebglyss, and a new indication for Zepbound in obstructive sleep apnea.

2025 Financial Guidance

Expected revenue growth of approximately 32% compared to 2024, driven by continued incretin class growth and new market launches.

---

Eli Lilly & Co (DE:LLY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:LLY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 01, 2025	2025 (Q1)	4.48 / -	2.46	―	―	―
Feb 06, 2025	2024 (Q4)	4.81 / 5.07	2.374	113.65% (+2.70)
Oct 30, 2024	2024 (Q3)	1.36 / 1.13	0.095	1080.00% (+1.03)
Aug 08, 2024	2024 (Q2)	2.62 / 3.74	2.012	85.78% (+1.73)
Apr 30, 2024	2024 (Q1)	2.35 / 2.46	1.545	59.26% (+0.92)
Feb 06, 2024	2023 (Q4)	2.19 / 2.37	1.993	19.14% (+0.38)
Nov 02, 2023	2023 (Q3)	-0.17 / 0.10	1.888	-94.95% (-1.79)
Aug 08, 2023	2023 (Q2)	1.89 / 2.01	1.192	68.80% (+0.82)
Apr 27, 2023	2023 (Q1)	1.65 / 1.54	2.498	-38.17% (-0.95)
Feb 02, 2023	2022 (Q4)	1.70 / 1.99	2.374	-16.06% (-0.38)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DE:LLY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 06, 2025	€800.24	€847.06	+5.85%
Oct 30, 2024	€831.42	€765.74	-7.90%
Aug 08, 2024	€706.55	€759.99	+7.56%
Apr 30, 2024	€678.31	€715.47	+5.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---